Biopharma · FDA Approvals · Stock
ADMA ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA B…
Assets on file: ASCENIV
Catalyst calendar
Dated catalysts for ADMA, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for ADMA, newest first.
ADMAADMA BiologicsADMA Biologics: FDA expands ASCENIV label to pediatric PI patients ≥2 years
FDA approved the sBLA that removes the prior age restriction, now allowing ASCENIV use in PI patients two years of age and older. The expanded label fulfills the post-marketing pediatric study commitment and broadens the addressable patient population from age 12+ to age 2+.
Peers by market cap
Companies in the same sector closest to ADMA in market value.
PGENPrecigenMarket cap $2.5B · 2 tracked drugs
ZLABZai LabMarket cap $2.5B · 3 tracked drugs · 7 upcoming catalysts
SUPNSupernusMarket cap $2.4B · 1 tracked drug
NAMSNewAmsterdamMarket cap $2.4B · 1 tracked drug · 6 upcoming catalysts
CLDXCelldexMarket cap $2.4B · 1 tracked drug · 2 upcoming catalysts
BHVNBiohavenMarket cap $2.3B · 4 tracked drugs · 5 upcoming catalysts
VRDNViridian TherapeuticsMarket cap $2.8B · 2 tracked drugs
RCUSArcus BiosciencesMarket cap $2.3B · 1 tracked drug · 4 upcoming catalysts